2024
A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System
Haque L, Tate J, Chew M, Caniglia E, Taddei T, Re V. A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System. Pharmacoepidemiology And Drug Safety 2024, 33: e70024. PMID: 39477692, DOI: 10.1002/pds.70024.Peer-Reviewed Original ResearchConceptsVeterans Health Administration dataHealth administrative dataAdministrative dataElectronic health record systemsHealth record systemsInternational Classification of DiseasesCoding algorithmOutpatient International Classification of DiseasesPositive predictive valueClassification of DiseasesHepatic decompensationDiagnosis codesPharmacoepidemiologic researchMedical recordsVeteransRecording systemValidation algorithmAlgorithmChronic liver diseaseDecompensationLiver diseasePredictive valueRecordsDiagnosisClinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes
Zhang T, Niu N, Taddei T, Jain D, Zhang X. Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal Of Clinical Pathology 2024, aqae136. PMID: 39418121, DOI: 10.1093/ajcp/aqae136.Peer-Reviewed Original ResearchSH-HCCSteatohepatitic hepatocellular carcinomaHepatocellular carcinomaLiver diseaseHepatitis C virus infectionC virus infectionStage of fibrosisPresence of steatohepatitisOverall survivalHistological subtypesPrognostic factorsHCC subtypesBackground liverHCC casesClinicopathological featuresConventional HCCHistopathological patternsHyaline globulesTumor cellsMallory-Denk bodiesGlycogenated nucleiSteatotic liver diseaseHCCSurvival analysisSteatohepatitisIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reportsSafety of naltrexone in patients with cirrhosis
Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Reports 2024, 6: 101095. PMID: 38961852, PMCID: PMC11220533, DOI: 10.1016/j.jhepr.2024.101095.Peer-Reviewed Original ResearchDrug-induced liver injuryRoussel Uclaf Causality Assessment MethodAlcohol use disorderInitiation of naltrexoneSafety of naltrexoneUse disorderRetrospective studyDevelopment of drug-induced liver injuryRoussel Uclaf Causality Assessment Method scoreLiver injuryLiver diseaseRetrospective study of patientsTreatment of alcohol use disordersTreat alcohol use disorderLiver enzyme elevationAlcohol-related cirrhosisCohort of patientsAlkaline phosphatase elevationDiagnosis of cirrhosisStudy of patientsAssociated with developmentCausality Assessment MethodPrescribed naltrexoneDecompensated cirrhosisEnzyme elevationAccuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024 PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Original ResearchAminotransferase-to-platelet ratio indexChronic liver diseaseNonalcoholic fatty liver diseaseHepatitis B virusBlood-based biomarkersLiver diseaseFIB-4HIV-HCV co-infectionCo-infectionFIB-4 <Alternative to liver biopsyFIB-4 >Pre-test probabilityBlood-based testLiver disease assessmentSystematic reviewStaging liver fibrosisComprehensive search of databasesHIV-HCVFatty liver diseaseProportional odds ratiosAdvanced fibrosisLiver biopsyViral hepatitisB virus
2023
Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project
Rogal S, Taddei T, Monto A, Yakovchenko V, Patton H, Merante M, Spoutz P, Chia L, Yudkevich J, Aytaman A, Rabiee A, John B, Blechacz B, Cai C, Gilles H, Shah A, McCurdy H, Puri P, Jou J, Mazhar K, Dominitz J, Anwar J, Morgan T, Ioannou G. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clinical Gastroenterology And Hepatology 2023, 22: 324-338. PMID: 37460005, PMCID: PMC10788380, DOI: 10.1016/j.cgh.2023.07.002.Peer-Reviewed Original ResearchGood performance statusCurative treatmentHCC screeningHCC diagnosisPerformance statusEarly-stage diagnosisMedical record extractionAdvanced liver diseaseReceipt of treatmentStage diagnosisPreventative health care servicesHepatocellular carcinoma stageVA primary careQuality improvement projectHealth care servicesHepatocellular carcinoma diagnosisElectronic health recordsCirrhosis careNoncurative treatmentLiver diseaseCancer screeningPrimary careMultivariable modelCarcinoma stageNew diagnosisMedications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol useEnhanced Identification of Hispanic Ethnicity Using Clinical Data
Ochoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.Peer-Reviewed Original ResearchConceptsBurden of diseaseHispanic patientsCountry of birthClinical dataHispanic ethnicityNon-Hispanic white patientsSex-adjusted prevalenceChronic liver diseaseHuman immunodeficiency virusDemographic characteristicsElectronic health record dataHealth careHealth record dataPrevalence of conditionsUS health care systemMedicare administrative dataHealth care systemWhite patientsLiver diseaseImmunodeficiency virusSelf-reported ethnicityHigh prevalenceGastric cancerHepatocellular carcinomaVeteran population
2022
Attacking the public health crisis of hepatocellular carcinoma at its roots
Lee HM, Lidofsky SD, Taddei TH, Townshend‐Bulson L. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022, 77: 1456-1459. PMID: 35989555, PMCID: PMC10026951, DOI: 10.1002/hep.32741.Peer-Reviewed Original ResearchConceptsHepatitis B virusLiver diseasePublic health crisisHepatocellular carcinomaChronic hepatitis B virusAlcohol-related liver diseaseNonalcoholic fatty liver diseaseChronic liver diseaseFatty liver diseasePrincipal risk factorsCancer-related deathSignificant mortality ratePrevention of HCCHealth crisisViral hepatitisTreatment advancesB virusRisk factorsCurable stageCommon causeRisk populationsHCC detectionRisk individualsMortality rateSurveillance programHolistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentCOVID-19 and the liver: a narrative review of the present state of knowledge
Thandassery RB, Dranoff JA, Perisetti A, Taddei T. COVID-19 and the liver: a narrative review of the present state of knowledge. Translational Gastroenterology And Hepatology 2022, 0: 0-0. PMID: 36300154, PMCID: PMC9468988, DOI: 10.21037/tgh-20-243.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseLiver diseaseLiver injuryComorbid conditionsAcute respiratory distress syndromeDirect viral cytotoxicityNon-immunosuppressed patientsAdvanced liver diseaseLiver function testsThird of patientsEpithelial cellsRespiratory distress syndromeResolution of diseaseResolution of illnessOngoing pandemicNovel corona virus diseaseType 2 pneumocytesCOVID-19Biliary epithelial cellsGastrointestinal epithelial cellsCorona Virus DiseaseLiver dysfunctionDistress syndromeFunction testsUninterrupted careQuality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El‐Serag H, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022, 75: 1289-1299. PMID: 34778999, DOI: 10.1002/hep.32240.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesHigh-risk populationHCC careCare continuumBarcelona Clinic Liver Cancer (BCLC) stagingData System (BI-RADS) 4 lesionsBurden of HCCLiver transplantation candidacyTumor board reviewLiver Imaging ReportingFear of treatmentStructured scoping reviewExplicit quality measuresAmerican AssociationTransplantation candidacyBest individual treatmentPalliative therapyGuideline recommendationsLiver diseaseAFP elevationAppropriate referralTreatment optionsTreatment recommendationsCancer stagingOutcome measuresStatin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort
Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal Of Hepatology 2022, 76: 1100-1108. PMID: 35066085, PMCID: PMC9018495, DOI: 10.1016/j.jhep.2021.12.034.Peer-Reviewed Original ResearchConceptsChronic liver failureStatin exposureLiver failureStatin useCohort studyChronic liver failure developmentInverse probability treatment weightingProportional hazards regression modelsDoses of statinsVeterans Affairs cohortRetrospective cohort studyChronic liver diseaseHazards regression modelsLarge national cohortVeterans Health AdministrationNumerous beneficial effectsMarginal structural modelsMedian followStatin therapyLiver diseaseNational cohortACLFTreatment weightingCirrhosisPatientsImpact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances In Gastroenterology 2022, 15: 17562848221100106. PMID: 36199289, PMCID: PMC9527996, DOI: 10.1177/17562848221100106.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseImpact of NAFLDBody mass indexOverall survivalHepatocellular carcinomaLiver diseasePresence of NAFLDMultivariable Cox proportional hazardsMedian body mass indexAdvanced-stage hepatocellular carcinomaGrade 2 hypertensionLower starting doseInternational cohort studySimilar clinical benefitsFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseAdverse eventsCohort studyPrognostic factorsClinical outcomesMass indexClinical benefitOral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study
Wang Z, Budhu AS, Shen Y, Wong LL, Hernandez BY, Tiirikainen M, Ma X, Irwin ML, Lu L, Zhao H, Lim JK, Taddei T, Mishra L, Pawlish K, Stroup A, Brown R, Nguyen MH, Koshiol J, Hernandez MO, Forgues M, Yang H, Lee M, Huang Y, Iwasaki M, Goto A, Suzuki S, Matsuda K, Tanikawa C, Kamatani Y, Mann D, Guarnera M, Shetty K, Thomas CE, Yuan J, Khor CC, Koh W, Risch H, Wang XW, Yu H. Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study. JGH Open 2021, 5: 1363-1372. PMID: 34950780, PMCID: PMC8674550, DOI: 10.1002/jgh3.12682.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseCase-control studyHepatocellular carcinomaSingle nucleotide polymorphismsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionGenetic susceptibilityC virus infectionLong-term alcohol useFatty liver diseaseUS case-control studyBody mass indexMajor risk factorGenome-wide association studiesHCV infectionCohort studyLiver diseaseCigarette smokingMass indexRisk factorsHCC casesVirus infectionGene-environment interactionsUS populationDisease riskPalliative Care Always: Hepatology—Virtual Primary Palliative Care Training for Hepatologists
DeNofrio JC, Verma M, Kosinski AS, Navarro V, Taddei TH, Volk ML, Bakitas M, Ramchandran K. Palliative Care Always: Hepatology—Virtual Primary Palliative Care Training for Hepatologists. Hepatology Communications 2021, 6: 920-930. PMID: 34719137, PMCID: PMC8948550, DOI: 10.1002/hep4.1849.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseasePalliative carePrimary palliative carePalliative care skillsPalliative care trainingRoutine patient carePsychological symptom managementPC skillsLiver diseaseSymptom managementPractice patternsPost-knowledge assessmentSerious illnessCare skillsHepatologistsPatient carePsychosocial supportCare trainingPatientsCareCompletion of courseworkKnowledge assessmentCourseHepatologyIllnessHepatocellular Carcinoma
Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma. American Journal Of Clinical Pathology 2021, 157: 305-313. PMID: 34542582, DOI: 10.1093/ajcp/aqab125.Peer-Reviewed Original ResearchConceptsAnaplastic tumor cellsHepatocellular carcinomaNoncirrhotic liverVascular invasionHistologic patternCirrhotic liverTumor cellsClear cell subtypePathogenesis of HCCHigh histologic gradeLarger tumor sizeHigher tumor stageHigh tumor gradeHigh rateHepatitis BHepatitis CLiver diseaseTumor sizeHistologic gradeTumor stageTumor gradePathologic differencesHCC casesRetrospective analysisPathology archivesInpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts
Serper M, Kaplan DE, Lin M, Taddei TH, Parikh ND, Werner RM, Tapper EB. Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. Digestive Diseases And Sciences 2021, 67: 2094-2104. PMID: 34374917, PMCID: PMC10849043, DOI: 10.1007/s10620-021-07150-8.Peer-Reviewed Original ResearchConceptsLength of stayPropensity-matched analysisNational cohortSpecialty careHigher LOSAlcohol-associated hepatitisCirrhosis-related admissionsOutcome of cirrhosisSpontaneous bacterial peritonitisLarge national cohortCirrhosis complicationsHepatology consultationVA cohortIndex admissionGastroenterology consultationClinical characteristicsBacterial peritonitisLiver diseaseReadmission riskICD9/10 codesRisk regressionInpatient consultationsPatientsLower mortalityDisease severityImpact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDiabetes mellitusLiver diseaseNon-alcoholic fatty liver diseaseCotransporter 2 inhibitorsChronic liver diseaseFatty liver diseaseVeterans Affairs hospitalIncidence of ascitesAdditional pharmacotherapyTreat analysisElectronic health dataSGLT2 inhibitorsSGLT2i usersSurrogate biomarkerDPP4 inhibitorsMetabolic effectsPatientsCirrhosisPropensity scoreAscitesConfirmatory studiesMetformin